UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

 

 

iTeos Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

46565G104

(CUSIP Number)

Luke Evnin

MPM Asset Management

450 Kendall Street

Cambridge, MA 01242

Telephone: (617) 425-9200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 16, 2021

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.   ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

Page 1


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2014, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  1,927,595

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  1,927,595

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,927,595

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  5.5%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This schedule is filed by MPM BioVentures 2014, L.P. (“BV 2014”), MPM BioVentures 2014 (B), L.P. (“BV 2014(B)”), MPM Asset Management Investors BV2014 LLC (“AM BV2014 LLC”), MPM BioVentures 2018, L.P. (“BV 2018”), MPM BioVentures 2018 (B), L.P. (“BV 2018(B)”), MPM Asset Management Investors BV2018 LLC (“AM BV2018 LLC”), UBS Oncology Impact Fund L.P. (“UBS Oncology”), MPM BioVentures 2014 GP LLC (“BV 2014 GP”), MPM BioVentures 2014 LLC (“BV 2014 LLC”), MPM BioVentures 2018 GP LLC (“BV 2018 GP”), MPM BioVentures 2018 LLC (“BV 2018 LLC”), Oncology Impact Fund (Cayman) Management LP (“Oncology Cayman”) and BioImpact Capital LLC (“BioImpact”) (collectively, the “MPM Entities”) and Ansbert Gadicke, Luke Evnin, Todd Foley and Edward Hurwitz (collectively, the “Listed Persons” and together with the MPM Entities, the “Filing Persons”). The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of iTeos Therapeutics, Inc. (the “Issuer”), as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 2


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2014 (B), L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  107,713

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  107,713

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  107,713

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.3%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 3


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM Asset Management Investors BV2014 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  66,347

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  66,347

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  66,347

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.2%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 4


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2018, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  1,217,428

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  1,217,428

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,217,428

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  3.5%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 5


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2018 (B), L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  54,213

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  54,213

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  54,213

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.2%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 6


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM Asset Management Investors BV2018 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  24,026

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  24,026

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  24,026

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.1%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 7


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  UBS Oncology Impact Fund, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  2,178,890

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  2,178,890

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  2,178,890

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  6.2%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 8


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2014 GP LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  2,035,308(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  2,035,308(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  2,035,308(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  5.8%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,927,595 shares held by BV 2014 and 107,713 shares held by BV 2014(B). BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B).

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 9


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2014 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  2,101,655(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  2,101,655(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  2,101,655(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  6.0%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,927,595 shares held by BV 2014, 107,713 shares held by BV 2014(B) and 66,347 shares held by AM BV2014 LLC. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014 LLC

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 10


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2018 GP LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,271,641(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,271,641(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,271,641(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  3.6%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,217,428 shares held by BV 2018 and 54,213 shares held by BV 2018(B). BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B).

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 11


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  MPM BioVentures 2018 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,295,667(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,295,667(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,295,667(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  3.7%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,217,428 shares held by BV 2018, 54,213 shares held by BV 2018(B) and 24,026 shares held by AM BV2018 LLC. BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018 LLC.

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 12


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  Oncology Impact Fund (Cayman) LP

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  2,178,890(2)

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  2,178,890(2)

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  2,178,890(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

  6.2%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Consists of shares held by UBS Oncology. BioImpact is the General Partner of Oncology (Cayman), the General Partner of UBS Oncology.

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 13


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  BioImpact Capital LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  2,178,890(2)

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  2,178,890(2)

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  2,178,890(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  6.2%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Consists of shares held by UBS Oncology. BioImpact is the general partner Oncology (Cayman), the General Partner of UBS Oncology.

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 14


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  Ansbert Gadicke

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  5,576,212(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  5,576,212(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  5,576,212(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  15.8(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,927,595 shares held by BV 2014, 107,713 shares held by BV 2014(B), 66,347 shares held by AM BV 2014 LLC, 1,217,428 share held by BV 2018, 54,213 shares held by BV 2018(B), 24,026 shares held by AM BV 2018 LLC and 2,178,890 shares held by UBS Oncology. The Reporting Person is a managing director of BV 2014 LLC and BV2018 LLC and the managing partner of BioImpact.

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 15


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  Luke Evnin

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  3,397,322(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  3,397,322(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  3,397,322(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  9.6%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,927,595 shares held by BV 2014, 107,713 shares held by BV 2014(B), 66,347 shares held by AM BV 2014 LLC, 1,217,428 share held by BV 2018, 54,213 shares held by BV 2018(B) and 24,026 shares held by AM BV 2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 16


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  Todd Foley

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  3,397,322(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  3,397,322(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  3,397,322(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  9.6%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,927,595 shares held by BV 2014, 107,713 shares held by BV 2014(B), 66,347 shares held by AM BV 2014 LLC, 1,217,428 share held by BV 2018, 54,213 shares held by BV 2018(B) and 24,026 shares held by AM BV 2018 LLC. The Reporting Person is managing director of BV 2014 LLC and BV 2018 LLC.

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 17


CUSIP No. 46565G104

 

  1.    

  Name of Reporting Persons.

 

  Edward Hurwitz

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒(1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,295,667(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,295,667(2)

11.  

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,295,667(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  3.7%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,217,428 shares held by BV 2018, 54,213 shares held by BV 2018(B) and 24,026 shares held by AM BV 2018 LLC . The Reporting Person is a managing director of BV 2018 LLC.

(3)

This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

 

Page 18


This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the “Common Stock”), of iTeos Therapeutics Inc. (the “Issuer”), as filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2020 (the “Original Schedule 13D”). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales and distributions in kind of the Issuer’s Common Stock by certain Filing Persons.

Items 2, 4, 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 3 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

 

Item 2.

Identity and Background

(a) The entities and persons filing this statement are MPM BioVentures 2014, L.P. (“BV 2014”), MPM BioVentures 2014 (B), L.P. (“BV 2014(B)”), MPM Asset Management Investors BV2014 LLC (“AM BV2014 LLC”), MPM BioVentures 2018, L.P. (“BV 2018”), MPM BioVentures 2018 (B), L.P. (“BV 2018(B)”), MPM Asset Management Investors BV2018 LLC (“AM BV2018 LLC”), UBS Oncology Impact Fund L.P. (“UBS Oncology”), MPM BioVentures 2014 GP LLC (“BV 2014 GP”), MPM BioVentures 2014 LLC (“BV 2014 LLC”),”), MPM BioVentures 2018 GP LLC (“BV 2018 GP”), MPM BioVentures 2018 LLC (“BV 2018 LLC”), Oncology Impact Fund (Cayman) Management LP (“Oncology Cayman”) and BioImpact Capital LLC (“BioImpact”) (collectively, the “MPM Entities”) and Ansbert Gadicke, Luke Evnin, Todd Foley and Edward Hurwitz (collectively, the “Listed Persons” and together with the MPM Entities, the “Filing Persons”).

(b) The address of the principal place of business for each of the MPM Entities and Ansbert Gadicke, Luke Evnin, Todd Foley and Edward Hurwitz is 450 Kendall Street, Cambridge, MA 02142, other than Oncology Cayman whose address is 1st Floor, 2 Hill Street, St Helier, Jersey, JE1 4FS.

(c) The principal business of each of the Filing Persons is the venture capital investment business.

(d) During the last five years, none of the Filing Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, none of the Filing Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Each of the Listed Persons is a United States citizen and each of the MPM Entities is a Delaware limited partnership or limited liability company, other than Oncology Cayman which is a Cayman Islands limited partnership.

In accordance with the provisions of General Instruction C to Schedule 13D, information concerning the managers and each other person controlling the general partners of the MPM Entities required by Item 2 of Schedule 13D is listed on Schedule 1 hereto and is incorporated by reference herein.

 

Item 4.

Purpose of Transaction

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

The MPM Entities sold an aggregate of 438,998 shares of Common Stock in open market transactions from April 7, 2021 through September 20, 2021 for aggregate gross proceeds of $12,556,896. On April 7, 2021, BV 2014(B) distributed an aggregate of 10,424 shares of Common Stock in a pro rata in-kind distribution to its limited partners for no consideration and BV 2018(B) distributed an aggregate of 5,426 shares of Common Stock in a pro rata in-kind distribution to its limited partners for no consideration. On September 7, 2021, BV 2014(B) distributed an aggregate of 20,848 shares of Common Stock in a pro rata in-kind distribution to its limited partners for no consideration and BV 2018(B) distributed an aggregate of 10,492 shares of Common Stock in a pro rata in-kind distribution to its limited partners for no consideration.

 

Page 19


Item 5.

Interest in Securities of the Issuer

(a) – (b) The following information with respect to the ownership of the Common Stock of the Issuer by the Filing Persons is provided as of September 20, 2021:

 

Reporting Person

   Shares
Held
Directly
     Sole Voting
Power
     Shared
Voting
Power
     Sole
Dispositive
Power
     Shared
Dispositive
Power
     Beneficial
Ownership
     Percentage
of Class (1)
 

BV 2014

     1,927,595        1,927,595        0        1,927,595        0        1,927,595        5.5

BV 2014(B)

     107,713        107,713        0        107,713        0        107,713        0.3

AM BV 2014 LLC

     66,347        66,347        0        66,347        0        66,347        0.2

BV 2018

     1,217,428        1,217,428        0        1,217,428        0        1,217,428        3.5

BV 2018(B)

     54,213        54,213        0        54,213        0        54,213        0.2

AM BV 2018 LLC

     24,026        24,026        0        24,026        0        24,026        0.1

UBS Oncology

     2,178,890        2,178,890        0        2,178,890        0        2,178,890        6.2

BV 2014 GP(2)

     0        0        2,035,308        0        2,035,308        2,035,308        5.8

BV 2014 LLC(3)

     0        0        2,101,655        0        2,101,655        2,101,655        6.0

BV 2018 GP(4)

     0        0        1,271,641        0        1,271,641        1,271,641        3.6

BV 2018 LLC(5)

     0        0        1,295,667        0        1,295,667        1,295,667        3.7

Oncology Cayman(6)

     0        0        2,178,890        0        2,178,890        2,178,890        6.2

BioImpact(6)

     0        0        2,178,890        0        2,178,890        2,178,890        6.2

Ansbert Gadicke(7)

     0        0        5,576,212        0        5,576,212        5,576,212        15.8

Luke Evnin(8)

     0        0        3,397,322        0        3,397,322        3,397,322        9.6

Todd Foley(8)

     0        0        3,397,322        0        3,397,322        3,397,322        9.6

Edward Hurwitz(9)

     0        0        1,295,667        0        1,295,667        1,295,667        3.7

 

(1)

This percentage is calculated based upon 35,209,755 outstanding common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

(2)

Includes securities held by BV 2014 and BV 2014(B). BV 2014 GP is the direct general partner of BV 2014 and BV 2014(B).

(3)

Includes securities held by BV 2014, BV2014(B) and AM BV 2014 LLC. BV 2014 LLC is the indirect general partner of BV 2014 and BV 2014(B) and the manager of AM BV 2014 LLC.

(4)

Includes securities held by BV 2018 and BV 2018(B). BV 2018 GP is the direct general partner of BV 2018 and BV 2018(B).

(5)

Includes securities held by BV 2018, BV 2018(B) and AM BV 2018 LLC. BV 2018 LLC is the indirect general partner of BV 2018 and BV 2018(B) and the manager of AM BV 2018 LLC.

(6)

Includes shares held by UBS Oncology. BioImpact is the General Partner of Oncology (Cayman), the General Partner of UBS Oncology.

 

Page 20


(7)

Includes securities held by BV 2014, BV 2014(B), AM BV 2014 LLC, BV 2018, BV 2018(B), AM BV 2018 LLC and UBS Oncology. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC and the managing partner of BioImpact.

(8)

Includes securities held by BV 2014, BV 2014(B), AM BV 2014 LLC, BV 2018, BV 2018(B), and AM BV 2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.

(9)

Includes shares held by BV 2018, BV 2018(B) and AM BV 2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

Each Filing Person disclaims membership in a “group.” Each Filing Person also disclaims beneficial ownership of any shares of the Issuer, except for the shares set forth in the table above next to the respective Filing Person’s name in subsection (b) of this Item 5.

The Reporting Persons sold the following Common Stock in the open market in the sixty days preceding the date of this filing:

 

Date of Sale

   Price Range      Average
Price
     Sold by
BV 2014
     Sold by
AM BV
2014 LLC
     Sold by
BV 2018
     Sold by
AM BV
2018 LLC
     Sold by UBS
Oncology
 

9/7/2021

   $ 28.89-$29.64      $ 29.18        18,156        625        11,467        226        20,522  

9/8/2021

   $ 28.02-$29.01      $ 28.61        6,644        229        4,196        83        7,511  

9/8/2021

   $ 29.04-$29.21      $ 29.10        560        19        354        7        633  

9/9/2021

   $ 28.29-$29.27      $ 28.97        13,539        466        8,551        169        15,303  

9/10/2021

   $ 27.455-$28.45      $ 27.86        4,027        139        2,544        50        4,553  

9/10/2021

   $ 28.46-$28.91      $ 28.73        4,034        139        2,547        51        4,559  

9/13/2021

   $ 27.17-$27.99      $ 27.64        12,740        439        8,046        159        14,401  

9/14/2021

   $ 26.91-$27.90      $ 27.50        10,687        368        6,750        133        12,080  

9/14/2021

   $ 27.92-$28.055      $ 27.99        2,159        74        1,363        27        2,440  

9/15/2021

   $ 27.12-$28.11      $ 27.79        13,770        474        8,697        172        15,564  

9/15/2021

   $ 28.13-$28.19      $ 28.15        591        20        373        7        668  

9/16/2021

   $ 27.885-$28.69      $ 28.47        12,662        436        7,997        158        14,312  

9/17/2021

   $ 28.50-$29.11      $ 28.82        27,226        937        17,195        340        30,775  

9/20/2021

   $ 26.535-$27.52      $ 27.03        6,317        217        3,990        78        7,141  

9/20/2021

   $ 27.53-$28.39      $ 27.84        8,163        281        5,156        101        9,229  
        

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
           141,275        4,863        89,226        1,761        159,691  
        

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

The information provided and incorporated by reference in Item 3 and Item 6 is hereby incorporated by reference in this Item 5.

 

  (d)

Inapplicable.

 

  (e)

Inapplicable.

 

Item 7.

Material to Be Filed as Exhibits

 

C.

Agreement regarding filing of joint Schedule 13D.

 

Page 21


Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 21, 2021

 

MPM BIOVENTURES 2014, L.P.
By:   MPM BioVentures 2014 GP LLC,
  its General Partner
By:   MPM BioVentures 2014 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2014 (B), L.P.
By:   MPM BioVentures 2014 GP LLC,
  its General Partner
By:   MPM BioVentures 2014 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM ASSET MANAGEMENT INVESTORS BV 2014 LLC
By:   MPM BioVentures 2014 LLC,
  Its Manager
By:  

/s/ Luke Evnin

Name:   Luke Evnin
  Title: Managing Director
MPM BIOVENTURES 2014 GP LLC
By:   MPM BioVentures 2014 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director

 

Page 22


MPM BIOVENTURES 2014 LLC
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2018, L.P.
By:   MPM BioVentures 2018 GP LLC,
  its General Partner
By:   MPM BioVentures 2018 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2018 (B), L.P.
By:   MPM BioVentures 2018 GP LLC,
  its General Partner
By:   MPM BioVentures 2018 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM ASSET MANAGEMENT INVESTORS BV 2018 LLC
By:   MPM BioVentures 2018 LLC,
  Its Manager
By:  

/s/ Luke Evnin

Name:   Luke Evnin
  Title: Managing Director
MPM BIOVENTURES 2018 GP LLC
By:   MPM BioVentures 2018 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2018 LLC
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director

 

Page 23


UBS ONCOLOGY IMPACT FUND, L.P.
By:   Oncology Impact Fund (Cayman) Management L.P.,
  its General Partner
By:   BioImpact Capital LLC
  Its General Partner
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
Title:   Managing Partner
ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.
By:   BioImpact Capital LLC
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
Title:   Managing Partner
BIOIMPACT CAPITAL LLC
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
Title:   Managing Partner
By:  

/s/ Todd Foley

Name:   Todd Foley
By:  

/s/ Luke Evnin

Name:   Luke Evnin
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
By:  

/s/ Edward Hurwitz

Name:   Edward Hurwitz

 

Page 24


Schedule I

General Partners/Members

Ansbert Gadicke

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2014 LLC, MPM BioVentures 2018 LLC and managing partner of BioImpact Capital LLC.

Citizenship: USA

Luke Evnin

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC.

Citizenship: USA

Todd Foley

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC.

Citizenship: USA

Edward Hurwitz

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2018 LLC.

Citizenship: USA

 

Page 25


Exhibit Index

 

C.

Agreement regarding filing of joint Schedule 13D.

 

Page 26

iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more iTeos Therapeutics Charts.
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more iTeos Therapeutics Charts.